Deltex Medical Group plc in a strong financial position

Nigel Keen, Chairman of Deltex Medical, commented:

“The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure.

“We made a number of changes to the Group in the first half – the appointment of a new CEO in June and a revised business strategy – which mean that Deltex Medical is much better positioned for the second half of the year and 2019.

“The lower cost base that the business now operates has given the Group a stronger platform from which to develop.

“Strategically we are now prioritising profitability over securing new customers – and believe that by working more closely with our existing customers we will start to generate incremental revenues more quickly from new product launches on the TrueVue System.”

Deltex Medical Group plc (LON: DEMG), the global leader in oesophageal doppler monitoring today announced its results for the six-month period ended 30 June 2018.

Operational highlights

Andy Mears appointed as CEO in mid-June

Revised strategy of building a stable business by focussing on driving revenues from existing customers

Programme of cost reduction and business stabilisation launched in the first half
– significantly accelerated and expanded since June with a significant reduction in sales and marketing costs

Focus on developing relationships with existing customers also expected to help the generation of incremental revenues from new TrueVue System product launches

Publication of the large multicentre FEDORA study showing a 76% reduction in total post-operative complications for low and moderate-risk patients using Deltex Medical’s oesophageal doppler haemodynamic monitoring technology

Financial highlights

A strong prior year comparator for Monitor sales and a number of one-off events associated with Probe revenues (including currency affects, changes in ordering by two large US accounts and a temporary inventory adjustment by a French distributor) resulted in revenues being held back to £2,325,000 (2017 H1: £2,877,000)

Substantial reductions in overheads: estimated annualised cost savings of c.£2,000,000 to be achieved from actions taken:

· c.£750,000 from actions prior to June

· c.£1,250,000 from actions since appointment of new CEO

33% reduction in employee numbers to 56 at 31 August (31 December 2017: 84)

30% reduction in sales and distribution costs to £1,373,000 (2017 H1: £1,949,000)

14% reduction in total costs to £2,796,000 (2017 H1: £3,265,000)

Operating loss (before exceptional costs) of £999,000 (2017 H1: £1,082,000)

Cash on balance sheet at 30 June 2018 of £1,065,000 (31 December 2017: £219,000)

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    Critical caring

    It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change

    Deltex Medical Group Plc

    FEDORA Study “Take-Homes” for clinicians

    Clinician-led disseminator of medical news, TopMedTalk has reviewed the landmark FEDORA study into Goal-Directed Haemodynamic Therapy (GDHT). Reinforcing the conclusions from meta-analysis of 70 other studies, FEDORA supports the use of Oesophageal Doppler to derive clinical parameters that